Interpace Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.15
- Today's High:
- $1.27
- Open Price:
- $1.15
- 52W Low:
- $0.51
- 52W High:
- $3.26
- Prev. Close:
- $1.14
- Volume:
- 7615
Company Statistics
- Market Cap.:
- $4.92 million
- Book Value:
- -14.428
- Revenue TTM:
- $37.37 million
- Operating Margin TTM:
- 2.33%
- Gross Profit TTM:
- $18.23 million
- Profit Margin:
- -40.79%
- Return on Assets TTM:
- 2.12%
- Return on Equity TTM:
- -284.81%
Company Profile
Interpace Biosciences Inc had its IPO on 1998-05-20 under the ticker symbol IDXG.
The company operates in the Healthcare sector and Diagnostics & Research industry. Interpace Biosciences Inc has a staff strength of 94 employees.
Stock update
Shares of Interpace Biosciences Inc opened at $1.15 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.15 - $1.27, and closed at $1.2.
This is a +5.26% increase from the previous day's closing price.
A total volume of 7,615 shares were traded at the close of the day’s session.
In the last one week, shares of Interpace Biosciences Inc have increased by +14.29%.
Interpace Biosciences Inc's Key Ratios
Interpace Biosciences Inc has a market cap of $4.92 million, indicating a price to book ratio of 10.0372 and a price to sales ratio of 0.1024.
In the last 12-months Interpace Biosciences Inc’s revenue was $37.37 million with a gross profit of $18.23 million and an EBITDA of $2.57 million. The EBITDA ratio measures Interpace Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Interpace Biosciences Inc’s operating margin was 2.33% while its return on assets stood at 2.12% with a return of equity of -284.81%.
In Q2, Interpace Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 49.1%.
Interpace Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.37 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Interpace Biosciences Inc’s profitability.
Interpace Biosciences Inc stock is trading at a EV to sales ratio of 0.2873 and a EV to EBITDA ratio of -1.2059. Its price to sales ratio in the trailing 12-months stood at 0.1024.
Interpace Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $15.94 million
- Total Liabilities
- $13.57 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $111000
- Dividend Payout Ratio
- 0%
Interpace Biosciences Inc ended 2024 with $15.94 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.94 million while shareholder equity stood at $-62206000.00.
Interpace Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $13.57 million in other current liabilities, in common stock, $-248491000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.08 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $11.31 million.
Interpace Biosciences Inc’s total current assets stands at $12.98 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.53 million compared to accounts payable of $1.69 million and inventory worth $1.18 million.
In 2024, Interpace Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $111000.
Comparatively, Interpace Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.2
- 52-Week High
- $3.26
- 52-Week Low
- $0.51
- Analyst Target Price
- $10.125
Interpace Biosciences Inc stock is currently trading at $1.2 per share. It touched a 52-week high of $3.26 and a 52-week low of $3.26. Analysts tracking the stock have a 12-month average target price of $10.125.
Its 50-day moving average was $1.62 and 200-day moving average was $1.35 The short ratio stood at 0.19 indicating a short percent outstanding of 0%.
Around 2860.5% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Interpace Biosciences Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.